In an otherwise healthy adult with acute cervical muscle pain and no gastrointestinal ulcer disease, severe renal impairment, uncontrolled hypertension, or high cardiovascular risk, which provides better pain relief, celecoxib or etoricoxib?

Celecoxib Provides Better Pain Relief with a Superior Safety Profile

For an otherwise healthy adult with acute cervical muscle pain, celecoxib is the preferred choice over etoricoxib, offering equivalent analgesic efficacy with better-established cardiovascular and gastrointestinal safety data at lower therapeutic doses.

Analgesic Efficacy

Both agents provide comparable pain relief for musculoskeletal conditions:

• Celecoxib demonstrated significant pain reduction within 24-48 hours in osteoarthritis studies, with 100-200 mg twice daily showing effectiveness similar to naproxen 500 mg twice daily 1
• Etoricoxib showed similar efficacy to nonselective NSAIDs and comparable effectiveness to celecoxib in osteoarthritis patients 2
• In direct comparisons, etoricoxib was significantly more effective than placebo and had similar efficacy to naproxen and diclofenac for pain relief 3
• Both agents provide effective analgesia for acute pain conditions, with celecoxib providing pain relief within 60 minutes in acute pain models 1

The analgesic efficacy is essentially equivalent between the two agents 4, 2, making safety profiles the determining factor.

Critical Safety Distinctions

Gastrointestinal Safety

• Celecoxib consistently demonstrates lower risk of gastroduodenal ulcers compared to nonselective NSAIDs, with significantly fewer upper GI complications 5, 6
• In elderly patients with knee osteoarthritis, celecoxib users were significantly less likely to suffer GI events than NSAID users (OR = 0.36,95% CI 0.21-0.63) 7
• Etoricoxib also showed fewer uncomplicated upper GI adverse events than nonselective NSAIDs, but had higher GI event rates than celecoxib in comparative studies (OR = 0.52 vs 0.36 for celecoxib) 7
• Celecoxib appears safer for both upper and lower GI tract complications 6

Cardiovascular Safety

• Celecoxib at recommended doses (100-200 mg twice daily) shows cardiovascular risk similar to or lower than nonselective NSAIDs 5, 8
• The PRECISION trial demonstrated celecoxib had significantly lower cardiorenal composite outcomes compared to ibuprofen (HR 0.67,95% CI 0.53-0.85) and a trend toward lower risk than naproxen 8
• Etoricoxib was noninferior to diclofenac for thrombotic cardiovascular events in the MEDAL program, but this comparison is less reassuring given diclofenac's known elevated CV risk 9
• Recent data shows diclofenac has comparable cardiovascular risks to etoricoxib, both higher than older COX-2 inhibitors 10

Dosing Considerations

• Celecoxib effective dose: 100-200 mg twice daily for acute pain, with 200 mg total daily dose often sufficient 1
• Etoricoxib typical dose: 90 mg once daily 7, which represents a higher relative COX-2 selectivity and potentially greater cardiovascular exposure
• The lower therapeutic doses required for celecoxib provide a safety margin, as cardiovascular risks appear dose-dependent 9

Regulatory and Guideline Context

• The American Heart Association emphasizes that celecoxib should be used at the lowest effective dose for the shortest duration, with careful consideration of cardiovascular risk factors 9
• Celecoxib remains on the US market with established safety monitoring, while etoricoxib is not FDA-approved in the United States 9
• Guidelines recommend COX-2 selective agents for patients at high risk of GI bleeding or those with history of intolerance to nonselective NSAIDs 9

Clinical Algorithm for Selection

Choose celecoxib 100-200 mg twice daily when:

• Patient requires effective analgesia for acute musculoskeletal pain
• No contraindications exist (uncontrolled hypertension, severe renal impairment, high CV risk)
• Treatment duration expected to be short (days to weeks for acute cervical pain)
• Patient has any GI risk factors (age >60, prior ulcer history, concurrent aspirin use)

Avoid both agents if:

• Patient has established cardiovascular disease requiring careful NSAID selection
• Severe renal impairment present (GFR <30 mL/min) 1
• Recent coronary artery bypass graft surgery 9

Key Clinical Caveats

• Concomitant aspirin use negates much of celecoxib's GI advantage over nonselective NSAIDs 9
• Both agents increase blood pressure; monitor in patients with hypertension 9
• Celecoxib has more extensive long-term safety data from the PRECISION trial, providing greater confidence in its risk profile 1, 8
• For acute cervical muscle pain, treatment duration should be limited to 5-7 days, minimizing cumulative cardiovascular and renal risks 9
• Drug exposure time significantly increases both GI and CV risks for all NSAIDs 7